Related Experiment Video
Updated: Jul 14, 2026
11:01
Preparation and In Vivo Use of an Activity-based Probe for N-acylethanolamine Acid Amidase
Published on: November 23, 2016
Solvent inclusion in form II carbamazepine
Aurora J Cruz Cabeza1, Graeme M Day, W D Samuel Motherwell
1The Pfizer Institute for Pharmaceutical Materials Science, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, UKCB2 1EW.
Chemical Communications (Cambridge, England)
|May 29, 2007
Summary
This study provides evidence for solvent inclusion in form II carbamazepine (R3). This finding impacts the formation and long-term stability of this important pharmaceutical compound.
Area of Science:
- Pharmaceutical Science
- Solid-State Chemistry
- Crystallography
Background:
- Carbamazepine is a widely used antiepileptic drug.
- Polymorphism in carbamazepine affects its bioavailability and therapeutic efficacy.
- Form II carbamazepine (R3) is a known polymorph with potential for solvent inclusion.
Purpose of the Study:
- To investigate the phenomenon of solvent inclusion in form II carbamazepine (R3).
- To elucidate the structural and thermodynamic implications of solvent inclusion.
- To understand how solvent inclusion influences the stability of carbamazepine form II.
Main Methods:
- Experimental techniques such as X-ray diffraction and thermal analysis.
- Computational modeling and theoretical calculations.
- Solvent interaction studies during crystallization.
Main Results:
- Conclusive experimental and theoretical evidence demonstrating solvent molecules incorporated within the crystal lattice of form II carbamazepine.
- Identification of specific solvent molecules and their binding sites.
- Correlation between the extent of solvent inclusion and observed changes in crystal habit and stability.
Conclusions:
- Solvent inclusion is a critical factor in the formation and stabilization of carbamazepine form II.
- Understanding solvent inclusion is essential for controlling carbamazepine polymorphism.
- This research provides insights for developing robust crystallization processes for pharmaceutical solids.
Related Concept Videos
03:00Solubility
Solution, Solubility, and Solubility Equilibrium
A solution is a homogeneous mixture composed of a solvent, the major component, and a solute, the minor component. The physical state of a solution—solid, liquid, or gas—is typically the same as that of the solvent. Solute concentrations are often described with qualitative terms such as dilute (of relatively low concentration) and concentrated (of relatively high concentration).
In a solution, the solute particles (molecules, atoms, and/or ions)...
A solution is a homogeneous mixture composed of a solvent, the major component, and a solute, the minor component. The physical state of a solution—solid, liquid, or gas—is typically the same as that of the solvent. Solute concentrations are often described with qualitative terms such as dilute (of relatively low concentration) and concentrated (of relatively high concentration).
In a solution, the solute particles (molecules, atoms, and/or ions)...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
02:55Solubility of Ionic Compounds
Solubility is the measure of the maximum amount of solute that can be dissolved in a given quantity of solvent at a given temperature and pressure. Solubility is usually measured in molarity (M) or moles per liter (mol/L). A compound is termed soluble if it dissolves in water.
04:01Factors Affecting Solubility
Compared with pure water, the solubility of an ionic compound is less in aqueous solutions containing a common ion (one also produced by dissolution of the ionic compound). This is an example of a phenomenon known as the common ion effect, which is a consequence of the law of mass action that may be explained using Le Chȃtelier’s principle. Consider the dissolution of silver iodide:
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...